BioCentury
ARTICLE | Clinical News

Agios discontinues development of AG-519 to treat pyruvate kinase deficiency

December 20, 2016 12:49 AM UTC

Agios said it discontinued development of AG-519 to treat pyruvate kinase deficiency after FDA placed a clinical hold on the candidate. On a conference call, the company said the hold was linked to a...

BCIQ Company Profiles

Agios Pharmaceuticals Inc.

BCIQ Target Profiles

Pyruvate kinase R